



ANNOUNCES A VIDEO ENCORE PRESENTATION FOR
IMN DEDICATED SATELLITE SITES ONLY

SPECIAL OFFER: Only IMN dedicated sites will receive this encore presentation via satellite on July 23rd. However, the first 1,000 sites to contact IMN and provide a list of potential physician attendees will receive a FREE VHS tape of the original broadcast from April 2, 2003.

THE IMPORTANCE OF SLEEP:

(Original live broadcast date April 2, 2003)

THE ROLE OF THE HEALTHCARE PROFESSIONAL

STATEMENT OF NEED

PLEASE ADJUST TIMES FOR YOUR TIMEZONE

Sleep disturbances are a very common concern among health practitioners of all disciplines. A 1999 self-report survey found that one in three adults experiences occasional insomnia. When relatively stringent criteria are used, the prevalence of insomnia in the general adult population is fairly consistent across epidemiologic studies, ranging from 9% to 17.7%. Of even greater concern is the fact that there are many persons suffering from sleep disorders like insomnia who never receive treatment. Mental healthcare specialists also see a huge number of patients suffering from sleep disorders. An NIMH study asked 7,954 respondents about their sleep complaints and psychiatric symptoms. A total of 10% of the respondents reported insomnia. Of those, 40% had one or more psychiatric disorders, compared with 16% of the respondents with no sleep complaints.

The first week in April marks National Sleep Awareness Week, and this year, our psychLINK cameras will be present at a national conference to capture the highlights. Join us for an exciting and highly educational presentation of information that healthcare professionals should know about this important clinical issue.

LEARNING OBJECTIVES

Upon completion of this activity, the participant should be able to:

- Define insomnia and explain its differential
- Identify the non-pharmacologic and pharmacologic treatment options for acute and chronic insomnia.
- Review strategies for the management of insomnia in special populations.

TARGET AUDIENCE

Physicians, Pharmacists and Nurses

CE CREDIT INSTRUCTIONS AND ACCREDITATION INFORMATION

Successful completion of this CE activity (EDA #550-0808) includes the following:

- View the video presentation and review the syllabus.
- Complete the appropriate CE application and activity evaluation form. Excluding physicians, participants must complete the post-test.
- Submit forms to the site coordinator for processing.

In the interest of full disclosure, please be advised that commercial supporters may obtain lists of registrants for demographic purposes and internal assessment of the activity's efficacy.

The duration of ACCME, ANCC and ACPE credit for this educational activity is three years from release date unless notified by IMN/PRIMEDIA Healthcare that the content is outdated.

Participants will receive a CE statement of credit within 4 weeks following receipt of the CE application and activity evaluation form. There is no fee for participating in this activity.

PHYSICIANS: PRIMEDIA Healthcare is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. PRIMEDIA Healthcare designates this educational activity for a maximum of 1.0 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity. This CME activity was planned and produced in accordance with the ACCME Essentials. This CME activity was planned and produced in accordance with the ACCME Essentials.

NURSES: This activity for 1.2 contact hour(s) is provided by PRIMEDIA Healthcare, a division of PRIMEDIA Workplace Learning, which is accredited as a provider of continuing education in nursing by the American Nurses Credentialing Center's Commission on Accreditation. Accreditation by the American Nurses Credentialing Center's Commission on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.



PHARMACISTS: PRIMEDIA Healthcare, a division of PRIMEDIA Workplace Learning, is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education.

CPE Credit: 1.0 contact hour or 0.10 CEU's
Universal Program Number: 775-999-03-015-H01

Viewing location for this encore presentation:

Additional dates for viewing this activity:

Date:	Time(s):	Location:
_____	_____	_____
Date:	Time(s):	Location:
_____	_____	_____

**Wednesday,
July 23, 2003**

Premiering for IMN Sites Only
12:30 – 1:30 PM EST and
Re-broadcast 3 PM EST

Via the web:

www.psychlink.com

MODERATOR

William Glazer, MD

Associate Clinical Professor of Psychiatry
Massachusetts General Hospital
Harvard Medical School
Boston, MA

FACULTY

Karl Doghramji, MD

Professor of Psychiatry
Jefferson Medical College &
Director, Sleep Disorders Center
Thomas Jefferson University Hospital
Philadelphia, PA

Milton Karl Erman, MD

President
Pacific Sleep Medicine Services
Clinical Professor of Psychiatry
University of California San Diego
Staff Scientist
The Scripps Research Institute
La Jolla, CA

**For more information or to Register
please call IMN at 888.466-3250.**

**This activity was supported by an
unrestricted educational grant from
Sanofi/Synthelabo.**



A division of
PRIMEDIA
Healthcare

The Gold Standard in CME



SPECIAL UNSCHEDULED LIVE BROADCAST

JUNE 26, 2003

NETWORKS:	IMN/HSTN/LTCN/JCSN/VHA
AIR DATE:	JUNE 26, 2003
AIR TIME:	12:00 PM – 2:30 PM EST
LENGTH:	150-minutes (2½ hours)
TITLE:	CENTER OF DISEASE CONTROL: ADULT IMMUNIZATION UPDATE
EDA NUMBER:	300-0351 HSTN / 319-0289 LTCN
PRODUCED BY:	CDC
CE AVAILABLE?	YES
HOW TO REGISTER:	www.phppo.cdc.gov/phtnonline
VIDEOTAPE BROADCAST?	YES, You may tape the broadcast
PERMISSION FOR REAIR?	YES

NOTE: Viewers are encouraged to review the CDC websites for all available information and updates (www.cdc.gov).

MILESTONES IN THE TREATMENT OF REFRACTORY SCHIZOPHRENIA

STATEMENT OF NEED

Despite advances in disease management, a substantial proportion of patients suffering from schizophrenia experience high relapse rates and report difficulty functioning in the community¹. These patients constitute the subgroup that is referred to as having "refractory schizophrenia." With the introduction of clozapine, the first of the second generation antipsychotic medications, researchers and clinicians have been keenly interested in how well these agents work for this group of refractory patients. Dr. John Kane is one of the leading experts in the use of antipsychotic medications in treatment refractory patients. As the principal author of the classic study of clozapine², Dr. Kane brings to this psychLINK program a wealth of expertise in this content area. Dr. Kane will update viewers on the most recent advances that have emerged in the treatment of patients with refractory schizophrenia and he will present important findings³ that his research team has recently completed. Joining Dr. Kane in a report from the field, Dr. Ralph Hoffman at Yale will detail some exciting findings that his group has generated in the use of transcranial stimulation (rTMS) for hallucinations in schizophrenic patients who now are partial or non-responders to antipsychotic agents.

1. Taylor DM; Duncan-McConnell D: Refractory schizophrenia and atypical antipsychotics. J Psychopharmacol 2000;14(4):409-18
2. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988; 45:789-96.
3. Leucht S, Barnes TRE, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new generation Antipsychotics: A systematic review and explorative meta-analysis of randomized controlled trials. American Journal of Psychiatry, in press.

LEARNING OBJECTIVES

Upon completion of this activity, the participant should be able to:

- Describe and critique the most recent studies of atypical antipsychotics as a treatment for refractory schizophrenia.
- Discuss the role that polypharmacy plays in the treatment of the non-responsive patient.
- Recognize the role that transcranial stimulation might play in the treatment of refractory hallucinations.

TARGET AUDIENCE

Physicians, Pharmacists and Nurses

CE CREDIT INSTRUCTIONS AND ACCREDITATION INFORMATION

Successful completion of this CE activity (EDA #550-0817) includes the following:

- View the video presentation and review the syllabus.
- Complete the appropriate CE application and activity evaluation form. Excluding physicians, participants must complete the post-test.
- Submit forms to the site coordinator for processing.

In the interest of full disclosure, please be advised that commercial supporters may obtain lists of registrants for demographic purposes and internal assessment of the activity's efficacy.

Participants will receive a CE statement of credit within 4 weeks following receipt of the CE application and activity evaluation form. There is no fee for participating in this activity.

PHYSICIANS: PRIMEDIA Healthcare, a division of PRIMEDIA Workplace Learning, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. PRIMEDIA Healthcare designates this educational activity for a maximum of 1.0 hour(s) in Category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity. This CME activity was planned and produced in accordance with the ACCME Essentials.

NURSES: This activity for 1.2 contact hour(s) is provided by PRIMEDIA Healthcare, a division of PRIMEDIA Workplace Learning, which is accredited as a provider of continuing education in nursing by the American Nurses Credentialing Center's Commission on Accreditation. Accreditation by the American Nurses Credentialing Center's Commission on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.



PHARMACISTS: PRIMEDIA Healthcare, a division of PRIMEDIA Workplace Learning, is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education.

CPE Credit: 1.0 contact hour or 0.10 CEUs
Universal Program Number:

775-999-032-L01 (live presentation)
775-999-032-H01 (videotape)

Viewing location for this live presentation:

Additional dates for viewing the recorded activity:

Date: _____ Time(s): _____ Location: _____

Date: _____ Time(s): _____ Location: _____

**WEDNESDAY,
AUGUST 6, 2003**

**12:30 – 1:30 PM EST
Rebroadcast 3 PM EST**

**Live on satellite and the web
at www.psychlink.com**

**For more information or
to Register your site,
please contact
IMN at 888.466.3250.**

MODERATOR

William Glazer, MD
Associate Clinical Professor of Psychiatry
Massachusetts General Hospital
Harvard Medical School
Boston, MA

FACULTY

John M. Kane, MD
Chairman, Department of Psychiatry
Albert Einstein College of Medicine
Executive Director of Behavioral Health Sciences
Hillside Hospital
A Division of Long Island Jewish Medical Center
Glen Oaks, New York

Ralph Hoffman, MD
Associate Professor of Psychiatry
Yale University School of Medicine
Assistant Medical Director
Yale-New Haven Psychiatric Hospital
New Haven, Connecticut

**This activity was supported by an
unrestricted educational grant
from Bristol-Myers Squibb
Company and Otsuka America
Pharmaceuticals, Inc.**



A division of
PRIMEDIA
Healthcare

The Gold Standard in CME

To be removed from our fax list please call 888.466.3250. Thank you.